150 related articles for article (PubMed ID: 35296644)
1. Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma.
Nijhuis A; Sikka A; Yogev O; Herendi L; Balcells C; Ma Y; Poon E; Eckold C; Valbuena GN; Xu Y; Liu Y; da Costa BM; Gruet M; Wickremesinghe C; Benito A; Kramer H; Montoya A; Carling D; Want EJ; Jamin Y; Chesler L; Keun HC
Nat Commun; 2022 Mar; 13(1):1380. PubMed ID: 35296644
[TBL] [Abstract][Full Text] [Related]
2. Aryl Sulfonamides Degrade RBM39 and RBM23 by Recruitment to CRL4-DCAF15.
Ting TC; Goralski M; Klein K; Wang B; Kim J; Xie Y; Nijhawan D
Cell Rep; 2019 Nov; 29(6):1499-1510.e6. PubMed ID: 31693891
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex.
Bussiere DE; Xie L; Srinivas H; Shu W; Burke A; Be C; Zhao J; Godbole A; King D; Karki RG; Hornak V; Xu F; Cobb J; Carte N; Frank AO; Frommlet A; Graff P; Knapp M; Fazal A; Okram B; Jiang S; Michellys PY; Beckwith R; Voshol H; Wiesmann C; Solomon JM; Paulk J
Nat Chem Biol; 2020 Jan; 16(1):15-23. PubMed ID: 31819272
[TBL] [Abstract][Full Text] [Related]
4. Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15.
Han T; Goralski M; Gaskill N; Capota E; Kim J; Ting TC; Xie Y; Williams NS; Nijhawan D
Science; 2017 Apr; 356(6336):. PubMed ID: 28302793
[TBL] [Abstract][Full Text] [Related]
5. Targeting the spliceosome through RBM39 degradation results in exceptional responses in high-risk neuroblastoma models.
Singh S; Quarni W; Goralski M; Wan S; Jin H; Van de Velde LA; Fang J; Wu Q; Abu-Zaid A; Wang T; Singh R; Craft D; Fan Y; Confer T; Johnson M; Akers WJ; Wang R; Murray PJ; Thomas PG; Nijhawan D; Davidoff AM; Yang J
Sci Adv; 2021 Nov; 7(47):eabj5405. PubMed ID: 34788094
[TBL] [Abstract][Full Text] [Related]
6. Proximity Labeling, Quantitative Proteomics, and Biochemical Studies Revealed the Molecular Mechanism for the Inhibitory Effect of Indisulam on the Proliferation of Gastric Cancer Cells.
Lu J; Jiang H; Li D; Chen T; Wang Y; Pu Z; Xu G
J Proteome Res; 2021 Sep; 20(9):4462-4474. PubMed ID: 34420308
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma.
Xu Y; Spear S; Ma Y; Lorentzen MP; Gruet M; McKinney F; Xu Y; Wickremesinghe C; Shepherd MR; McNeish I; Keun HC; Nijhuis A
Cell Rep; 2023 Oct; 42(10):113307. PubMed ID: 37858464
[TBL] [Abstract][Full Text] [Related]
8. Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820.
Du X; Volkov OA; Czerwinski RM; Tan H; Huerta C; Morton ER; Rizzi JP; Wehn PM; Xu R; Nijhawan D; Wallace EM
Structure; 2019 Nov; 27(11):1625-1633.e3. PubMed ID: 31693911
[TBL] [Abstract][Full Text] [Related]
9. Genetic and compound screens uncover factors modulating cancer cell response to indisulam.
Pogacar Z; Groot K; Jochems F; Dos Santos Dias M; Mulero-Sánchez A; Morris B; Roosen M; Wardak L; De Conti G; Velds A; Lieftink C; Thijssen B; Beijersbergen RL; Bernards R; Leite de Oliveira R
Life Sci Alliance; 2022 Sep; 5(9):. PubMed ID: 35534224
[TBL] [Abstract][Full Text] [Related]
10. Indisulam exerts anticancer effects via modulation of transcription, translation and alternative splicing on human cervical cancer cells.
Dou Z; Zhang X; Su W; Zhang T; Ye F; Zhao D; Chen X; Li Q; Zhang H; Di C
Am J Cancer Res; 2023; 13(7):2922-2937. PubMed ID: 37559979
[TBL] [Abstract][Full Text] [Related]
11. The aryl sulfonamide indisulam inhibits gastric cancer cell migration by promoting the ubiquitination and degradation of the transcription factor ZEB1.
Lu J; Li D; Jiang H; Li Y; Lu C; Chen T; Wang Y; Wang X; Sun W; Pu Z; Qiao C; Ma J; Xu G
J Biol Chem; 2023 Apr; 299(4):103025. PubMed ID: 36805336
[TBL] [Abstract][Full Text] [Related]
12. Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15.
Faust TB; Yoon H; Nowak RP; Donovan KA; Li Z; Cai Q; Eleuteri NA; Zhang T; Gray NS; Fischer ES
Nat Chem Biol; 2020 Jan; 16(1):7-14. PubMed ID: 31686031
[TBL] [Abstract][Full Text] [Related]
13. Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing associated with therapeutic response to splicing inhibitor.
Jablonowski CM; Quarni W; Singh S; Tan H; Bostanthirige DH; Jin H; Fang J; Chang TC; Finkelstein D; Cho JH; Hu D; Pagala V; Sakurada SM; Pruett-Miller SM; Wang R; Murphy A; Freeman K; Peng J; Davidoff AM; Wu G; Yang J
Elife; 2024 Mar; 12():. PubMed ID: 38488852
[TBL] [Abstract][Full Text] [Related]
14. RNA-binding motif protein 39 (RBM39): An emerging cancer target.
Xu Y; Nijhuis A; Keun HC
Br J Pharmacol; 2022 Jun; 179(12):2795-2812. PubMed ID: 33238031
[TBL] [Abstract][Full Text] [Related]
15. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
16. IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression.
Hagemann S; Misiak D; Bell JL; Fuchs T; Lederer MI; Bley N; Hämmerle M; Ghazy E; Sippl W; Schulte JH; Hüttelmaier S
Mol Cancer; 2023 May; 22(1):88. PubMed ID: 37246217
[TBL] [Abstract][Full Text] [Related]
17. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
[TBL] [Abstract][Full Text] [Related]
18. Quantitative Proteomics of Th-MYCN Transgenic Mice Reveals Aurora Kinase Inhibitor Altered Metabolic Pathways and Enhanced ACADM To Suppress Neuroblastoma Progression.
Hsieh CH; Cheung CHY; Liu YL; Hou CL; Hsu CL; Huang CT; Yang TS; Chen SF; Chen CN; Hsu WM; Huang HC; Juan HF
J Proteome Res; 2019 Nov; 18(11):3850-3866. PubMed ID: 31560547
[TBL] [Abstract][Full Text] [Related]
19. pSILAC method coupled with two complementary digestion approaches reveals PRPF39 as a new E7070-dependent DCAF15 substrate.
Jia X; Pan L; Zhu M; Hu H; Zhai L; Liu J; Hu M; Liu B; Tan M
J Proteomics; 2020 Jan; 210():103545. PubMed ID: 31626998
[TBL] [Abstract][Full Text] [Related]
20. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
Zhang S; Wei JS; Li SQ; Badgett TC; Song YK; Agarwal S; Coarfa C; Tolman C; Hurd L; Liao H; He J; Wen X; Liu Z; Thiele CJ; Westermann F; Asgharzadeh S; Seeger RC; Maris JM; Guidry Auvil JM; Smith MA; Kolaczyk ED; Shohet J; Khan J
Cancer Lett; 2016 Feb; 371(2):214-24. PubMed ID: 26683771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]